Humans have evolved over millennia with the microbes in and on our bodies. These microbes play a vital role in developing and directing immune and biological responses.
Evelo is harnessing the therapeutic potential of specific strains of naturally occurring microbes and developing them as a new class of medicines, monoclonal microbials.
We have validated that orally delivered monoclonal microbials modulate immunological and biological effects throughout the body after initial interactions with human cells in the gut.
Evelo is pioneering the development of this new class of medicine for the treatment of autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer.
Oncology Colon Cancer, Lung Cancer, Melanoma, Renal Cancer, Bladder Cancer
Immuno-Inflammatory Disease Psoriasis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Atopic Dermatitis, Food Allergy, Type I Diabetes
Neuro-Inflammation/Degeneration Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease
Neuro-CNS Autism, Anxiety, Depression
Metabolism Malnutrition, Type II Diabetes, Obesity, Nonalcoholic Fatty Liver Disease, Heart Disease
Vaccines Oral vaccines for autoimmune disease, infectious disease, and cancer; conditioning responses to current vaccines
We have discovered and are developing specific monoclonal microbials that modulate systemic biology.
These single strains impact multiple immunomodulatory pathways:
Mechanisms clinically relevant to treating cancer
Mechanisms clinically relevant to treating autoimmune and inflammatory diseases
We are advancing multiple monoclonal microbials with differentiated immunomodulatory activities through pre-clinical development and will start several clinical studies across oncology and immunoinflammatory diseases in 2018.
Biotech has helped many people through great science innovation in areas including monoclonal antibodies and targeted anti viral and oncology therapies.
Despite great success in treating many diseases, current healthcare is limited.
Currently, we treat late stages of diseases in a small portion of the world’s population with high cost drugs that have many side effects.
Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development.
By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, we can improve the speed, cost and probability of drug discovery and development.
Evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials.
Our leadership team has founded, led and grown some of the most important and transformative platform biotech companies and impacted many lives through the development of important medicines.
Evelo was founded by Flagship Pioneering, which conceives, creates,
resources and develops first-in-category life sciences companies.
Google Ventures, Celgene, Mayo Clinic and Alexandria Venture Investments
have joined Flagship Pioneering as investors in Evelo.
EVELO BIOSCIENCES ANNOUNCES ISSUANCE OF U.S. PATENT SUPPORTING MONOCLONAL MICROBIAL ONCOLOGY TRIALS
Cambridge, Mass. - January 9, 2018
EVELO BIOSCIENCES AND MAYO CLINIC COLLABORATE TO ADVANCE MONOCLONAL MICROBIALS FOR THE TREATMENT OF INFLAMMATORY AND NEUROINFLAMMATORY DISEASES
Cambridge, Mass. - November 16, 2017
EVELO BIOSCIENCES ANNOUNCES $50 MILLION SERIES B FINANCING AND EXPANSION OF BOARD AND LEADERSHIP TEAM
Cambridge, Mass. - July 11, 2017
UCHICAGO AND EVELO BIOSCIENCES SIGN LICENSING DEAL FOR MICROBIOME-BASED CANCER IMMUNOTHERAPY
Cambridge, Mass. - April 7, 2016
NOT YOUR MOM’S PROBIOTIC: GOOGLE-BACKED EVELO TEAMS UP WITH MAYO CLINIC ON MICROBIOME DRUGS
ENDPOINTS NEWS - November 16, 2017
AFTER RAISING $100M, GOOGLE-BACKED EVELO LOOKS TO BLAZE A NEW TRAIL WITH MONOCLONAL MICROBIALS
ENDPOINTS NEWS - July 11, 2017
A ONE-BUG DRUG FOR THE IMMUNE SYSTEM? EVELO GETS $50M TO TEST CONCEPT
Timmerman Report - July 11, 2017
GUT INSTINCT: LEVERAGING THE MICROBIOME AND HUMAN IMMUNE SYSTEM TO DRAMATICALLY TRANSFORM MEDICINE
WuXi AppTec - Innovation That Matters - May 17, 2017